November 3, 2015 / 12:07 PM / 2 years ago

BRIEF-Glaxosmithkline aims to file up to 20 new drugs for approval by 2020

Nov 3 (Reuters) - Glaxosmithkline Plc

* GSK profiles innovative research and development portfolio to investors

* 40 potential new medicines and vaccines offer significant opportunity to drive long-term performance and deliver new benefits to patients and consumers

* Approximately 80 of medicines and vaccines presented have potential to be “first-in-class” with novel mechanisms of action

* GSK has potential to file up to 20 assets with regulators before 2020

* Exploring new therapies for patients that could potentially enable long-term HIV control through infrequent dosing

* Expects core EPS to grow at a CAGR of mid-to-high single digits on a CER basis over five year period 2016-2020

* Phase III study with Daprodustat expected to begin in 2016

* Gsk profiles innovative research and development portfolio to investors

* Potential to file up to 20 assets with regulators before 2020

* During period 2021-2025, gsk has potential to file up to 20 additional innovative assets, now in clinical development

* Will work with national institute of allergy and infectious diseases to develop antibodies in long acting treatment and prevention of HIV Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below